Frederik Nevens
A5080844718- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Liver Diseases and Immunity
- Hepatitis B Virus Studies
- Renal Transplantation Outcomes and Treatments
- Pediatric Hepatobiliary Diseases and Treatments
- Genetic and Kidney Cyst Diseases
- Hepatocellular Carcinoma Treatment and Prognosis
- Gallbladder and Bile Duct Disorders
- Transplantation: Methods and Outcomes
- Alcohol Consumption and Health Effects
- Hepatitis Viruses Studies and Epidemiology
- Liver physiology and pathology
- Drug Transport and Resistance Mechanisms
- Clinical Nutrition and Gastroenterology
- Pancreatic function and diabetes
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Drug-Induced Hepatotoxicity and Protection
- Electrolyte and hormonal disorders
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Diet and metabolism studies
- Neurological Complications and Syndromes
KU Leuven
2016-2025
Universitair Ziekenhuis Leuven
2013-2024
European X-Ray Free-Electron Laser
2020-2023
Hull and East Yorkshire Hospitals NHS Trust
2023
National Health Service
2023
Hasselt University
2022
ERN RARE-LIVER
2022
Pomeranian Medical University
2011-2022
University Medical Center Groningen
2022
University of Groningen
2022
Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response therapy peginterferon alfa plus ribavirin.
Patients with cirrhosis in Child-Pugh class C or those B who have persistent bleeding at endoscopy are high risk for treatment failure and a poor prognosis, even if they undergone rescue transjugular intrahepatic portosystemic shunt (TIPS). This study evaluated the earlier use of TIPS such patients.We randomly assigned, within 24 hours after admission, total 63 patients acute variceal had been treated vasoactive drugs plus endoscopic therapy to polytetrafluoroethylene-covered stent 72...
Primary biliary cholangitis (formerly called primary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase bilirubin levels correlate with the risk of liver transplantation or death. Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients this disease.In 12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 who had an inadequate response found side effects unacceptable receive obeticholic...
Background & AimsElafibranor is an agonist of the peroxisome proliferator−activated receptor-α and receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, lipid metabolism reduces inflammation. We assessed safety efficacy elafibranor in international, randomized, double-blind placebo-controlled trial patients with nonalcoholic steatohepatitis (NASH).MethodsPatients NASH without cirrhosis were randomly assigned to groups given 80 mg (n = 93), 120 91), or placebo 92) each...
Acute-on-chronic liver failure (ACLF) in cirrhosis is characterized by acute decompensation (AD), organ failure(s), and high short-term mortality. Recently, we have proposed (systemic inflammation [SI] hypothesis) that ACLF the expression of an exacerbation SI already present decompensated cirrhosis. This study was aimed at testing this hypothesis included 522 patients with (237 ACLF) 40 healthy subjects. assessed measuring 29 cytokines redox state circulating albumin (HNA2), a marker...
Acute-on-chronic liver failure (ACLF) is a frequent cause of death in cirrhosis. Albumin dialysis with the molecular adsorbent recirculating system (MARS) decreases retained substances and improves hemodynamics hepatic encephalopathy (HE). However, its survival impact unknown. In all, 189 patients ACLF were randomized either to MARS (n=95) or standard therapy (SMT) (n=94). Ten (five per group) excluded due protocol violations. addition, 23 (MARS: 19; SMT: 4) from per-protocol (PP) analysis...
Aims: Cytokeratin (CK) 7 and CK19 expression, present in hepatic progenitor cells (HPCs) cholangiocytes but not normal hepatocytes, has been reported some hepatocellular carcinomas (HCCs); however, the incidence relevance of this expression HCC Caucasians is known. Therefore, our aim was to study occurrence clinicopathological characteristics expressing CK7 and/or 109 Caucasian patients. Methods results: The differentiation markers (Hepar, canalicular polyclonal carcinoembryonic antigen),...
•Patients with acutely decompensated cirrhosis without ACLF develop 3 different clinical courses.•Patients pre-ACLF within 90 days and have high systemic inflammation mortality.•Patients unstable suffer from complications of severe portal hypertension.•Patients stable less frequent lower 1-year mortality risk. Background & AimsAcute decompensation (AD) is defined as the acute development ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any combination thereof,...
Cholangiocellular carcinoma (CC) originates from topographically heterogeneous cholangiocytes. The cylindrical mucin-producing cholangiocytes are located in large bile ducts and the cuboidal non–mucin-producing ductules containing bipotential hepatic progenitor cells (HPCs). We investigated clinicopathological molecular features of 85 resected CCs (14 hilar [so-called Klatskin tumor], 71 intrahepatic [ICCs] including 20 cholangiolocellular carcinomas [CLCs], which thought to originate HPCs])...
Short-term patient and graft outcomes continue to improve after kidney liver transplantation, with 1-year survival rates over 80%; however, improving longer-term remains a challenge. Improving the function of grafts health recipients would not only enhance quality length life, but also reduce need for retransplantation, thus increase number organs available transplant. The clinical transplant community needs identify manage those modifiable factors, decrease risk failure, outcomes.COMMIT was...
Abstract Refractory hepatic encephalopathy (HE) remains a major cause of morbidity in cirrhosis patients. Large spontaneous portosystemic shunts (SPSSs) have been previously suggested to sustain HE these We aimed retrospectively assess the efficacy and safety patients treated with embolization large SPSSs for treatment chronic therapy-refractory European multicentric working group identify who may benefit from this procedure. Between July 1998 January 2012, 37 (Child A6-C13, MELD [Model...
<h3>Objective</h3> Keratin (K)19, a biliary/hepatic progenitor cell (HPC) marker, is expressed in subset of hepatocellular carcinomas (HCC) with poor prognosis. The underlying mechanisms driving this phenotype K19-positive HCC remain elusive. <h3>Design</h3> Clinicopathological value K19 was compared EpCAM, and α-fetoprotein, Caucasian cohort 242 consecutive patients (167 surgical specimens, 75 needle biopsies) different aetiologies. Using microarrays microRNA profiling the molecular HCCs...
The farnesoid X receptor (FXR) is a nuclear bile acid involved in homeostasis, hepatic and intestinal inflammation, liver fibrosis, cardiovascular disease. We studied the effect of short-term treatment with obeticholic (INT-747), potent selective FXR agonist, on intrahepatic hemodynamic dysfunction signaling pathways different rat models cirrhotic portal hypertension (PHT). For this, thioacetamide (TAA)-intoxicated bile-duct–ligated (BDL) rats were used as models. After gavage two doses 30...
Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory anti-fibrotic properties in preclinical PSC mouse model. A randomized controlled trial, including 38 centers from 12 European countries, evaluated the safety efficacy three doses oral norUDCA (500mg/d, 1,000mg/d or 1,500mg/d)...
Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents that are effective against all major HCV genotypes, with shorter treatment duration, needed to reduce disease burden. Glecaprevir (an NS3/4A protease inhibitor) pibrentasvir NS5A have a barrier resistance synergistic antiviral activity. We evaluated the safety efficacy of 8 12 weeks' glecaprevir/pibrentasvir in patients genotype 2, 4, 5, or 6 infection without cirrhosis 3 separate phase trials.We performed 2...